Ivy Natal was founded with the core mission of enabling genetic parenthood for individuals who are unable to conceive naturally due to surgery, chemotherapy, age, or genetic conditions. The company envisions a future where anyone can have biological children through innovative biotechnological solutions. Ivy Natal offers a groundbreaking service that creates egg cells from a simple skin biopsy, providing a new pathway to fertility for many who would otherwise rely on donor eggs.

Notable affiliated people and investors include leading experts in biotechnology and reproductive medicine, although specific names are not publicly disclosed. Ivy Natal has achieved significant milestones in developing its egg cell creation process and has garnered attention for its potential to revolutionize fertility treatments. The overall impact of Ivy Natal lies in its promise to transform the lives of countless individuals and couples by offering them the chance to have genetic children, thereby addressing a critical gap in reproductive healthcare.